文献速递炎症性肠病

维得利珠单抗扩展可及项目中治疗持续性与安全性的2年数据分析

Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.
PubMed 文献 · Aliment Pharmacol Ther · 2020-11-18

维得利珠单抗扩展可及项目(XAP)是一项3b/4期、前瞻性、开放标签、跨国干预研究,纳入311例(142例溃疡性结肠炎,169例克罗恩病)从GEMINI长期安全性研究转入的患者,在持续临床获益者中将给药频率从每4周一次降至每8周一次。结果显示,在入组时降至每8周给药的患者中,93.9%(UC)和91.6%(CD)维持每8周给药,6.1%(UC)和8.4%(CD)重新升级至每4周给药;降至每8周给药者中复发率为9.1%(UC)和14.0%(CD);与维得利珠单抗相关的不良事件不常见,未报告新发事件。

要点

  • 从GEMINI长期安全性研究转入XAP时持续临床获益的患者将给药频率从每4周一次降至每8周一次。
  • 入组时降至每8周给药者中,93.9%(UC)和91.6%(CD)维持每8周给药。
  • 降至每8周给药者中,复发率为9.1%(UC)和14.0%(CD),与维得利珠单抗相关的不良事件不常见。

核心结论

  • 在XAP中降低给药频率后的前2年内,维得利珠单抗每8周给药的患者持续性高,重新升级至每4周给药和复发的比率低,安全性特征与既往报告一致。

研究设计与样本

  • 维得利珠单抗XAP是一项3b/4期、前瞻性、开放标签、跨国干预研究,共纳入311例患者(142例溃疡性结肠炎和169例克罗恩病)。

主要发现

  • 基线时,93.7%(UC)和89.3%(CD)的患者处于临床缓解;93.0%(UC)和84.6%(CD)在入组时降至每8周给药。
  • 在入组时降至每8周给药的患者中,93.9%(UC)和91.6%(CD)维持每8周给药;6.1%(UC)和8.4%(CD)重新升级至每4周给药。
  • 降至每8周给药的患者中,报告复发者为9.1%(UC)和14.0%(CD)。
  • 与维得利珠单抗相关的不良事件不常见;未报告新发事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vedolizumab was shown to be effective and safe for patients with ulcerative colitis (UC) or Crohn's disease (CD) in the GEMINI phase 3 and long-term safety (LTS) studies. AIM: To report treatment persistence and safety results up to 2 years after enrolment in the vedolizumab extended access programme (XAP) METHODS: Vedolizumab XAP is a phase 3b/4, prospective, open-label, multinational, interventional study. At rollover from GEMINI LTS, patients who were experiencing continued clinical benefit with vedolizumab received reduced dosing frequency from every 4 weeks (Q4W) to every 8 weeks (Q8W). Patient persistence on Q8W dosing, incidence of relapse, and safety 2 years after enrolment were investigated. RESULTS: We enrolled 311 patients (142 UC and 169 CD). At baseline, 93.7% (UC) and 89.3% (CD) of patients were in clinical remission; 93.0% (UC) and 84.6% (CD) reduced dosing frequency to Q8W at enrolment. Of those who reduced dosing frequency to Q8W at enrolment, 93.9% (UC) and 91.6% (CD) remained on Q8W dosing; 6.1% (UC) and 8.4% (CD) re-escalated to Q4W dosing. Relapse was reported in 9.1% (UC) and 14.0% (CD) of patients who reduced dosing to Q8W. Adverse events related to vedolizumab were infrequent; no new events were reported. CONCLUSION: We observed high patient persistence on vedolizumab Q8W in the first 2 years after the reduction of dosing frequency in the XAP along with low rates of Q4W dose re-escalation and relapse. The safety profile was consistent with previous reports. ClinicalTrials.gov: NCT02743806.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Danese S, Subramaniam K, Van Zyl J, et al. Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. Aliment Pharmacol Ther. 2020. PMID: 33210333. doi:10.1111/apt.16160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。